The insistence of the FDA that only narrowly defined regimens are allowed in the control group in prospective randomized trials for drug registration has led to many undesirable consequences. American Journal of Transplantation
Can outcomes from recent major clinical trials in diabetic kidney disease be achieved in clinical practice? The British Journal of Diabetes and Vascular Disease
The investigational drug axitinib has shown activity in a phase 2 trial in cytokine-refractory renal cell carcinoma. Further studies are now in progress. Medscape Medical News
Reduced nephron number is hypothesized to be a risk factor for chronic kidney disease and hypertension. Whether reduced nephron number accelerates the early stages of diabetic nephropathy is unknown. Diabetes
Did the multivariate analyses using sex, age, tumor size, and symptomatology fail to produce a useful model to predict the pathology of individual tumors? American Journal of Clinical Pathology
